MROH2B and autoimmune hepatitis: Together, although current evidence is derived from animal models, sPIF is a promising therapeutic agent to treat multiple neurodegenerative disorders especially since sPIF crosses the blood-brain-barrier and received a FDA Fast Track Approval for first in human trial in autoimmune hepatitis, which was successfully completed36.